anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The inventions relate to the pharmaceutical industry, including pharmaceutical compositions forming the base of gels, and methods for producing gels which are intended mainly for preventing and/or treating anal fissures, haemorrhoids and diseases associated therewith and for reducing sensations of pain after a haemorrhoidectomy. The inventions relate to compositions and preparation methods, and also to the use of gels including nifedipine and lidocaine hydrochloride. The gels are prepared using nanotechnology. The technical result is achieved by producing such a composition of a gel including nifedipine and lidocaine hydrochloride, each variant of which provides for robustness of the gel properties, transparency, and preservation of the stability of the properties for up to 2 years, and the use of which makes it possible to reduce the clinical symptoms of haemorrhoids, up to and including complete elimination of said symptoms, to heal an anal fissure, and to relieve pain syndrome, including after a haemorrhoidectomy. Furthermore, the technical result is achieved by creating such a method for preparing a gel including nifedipine and lidocaine hydrochloride using nanotechnology, which provides for robustness of the gel properties, transparency, and preservation of the stability of the properties for up to 2 years. All the proposed inventions are industrially applicable, and laboratory tests have shown that the presented subject matter is practically implementable and will be extensively used in the pharmaceutical industry.

﻿
Evaluate the MTD of BNC105P in combination with ibrutinib in patients with relapsed/refractory CLL. Treatment will be administered on an outpatient basis but will also be permitted inpatient. BNC105P will be administered as a single agent prior to initiation of ibrutinib. Beginning with cycle 2, ibrutinib will be administered concomitantly with BNC105P at a starting dose of 420 mg PO daily. Each cycle will last for 21 days. Provided no toxicities occur, each patient will be treated for 6 cycles.
This trial will be carried out at the Grenoble Alpes University Hospital's simulation center. Volunteer professionals will run scenarios simulating the information transmission chain "pre-hospital team - trauma leader - trauma team" just prior to the admission of a critical patient to the trauma center. In each scenario, the trauma leader will be alerted by phone that a patient is being managed by a pre-hospital medical team and is about to be transferred to the trauma center. The trauma leader will have to synthesize and disseminate the available information to the trauma team (composed of a junior physician, a resident and a nurse). Depending on the allocation group, the transmission chain will be supported or not by a specific trauma dashboard. The scenario will be discontinued at the end of this handover and before the patient's arrival.
A delivery device applies a biocompatible and biodegradable barrier material to a tissue region, e.g., to seal a vascular puncture site. The material comprises two liquid components, which are pre-packaged in individual dispensers. Upon mixing, the liquid components cross-link to create a barrier matrix. A holder attaches to the delivery device. The holder mutually supports the first and second dispensers while the protein solution and polymer solution are conveyed from the dispensers into a fluid delivery channel. The protein and polymer solutions mix as a result of flow through the channel.
SIB-IMRT: Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.
The impact of chronic urticaria on work has been scarcely reported, whereas its peak incidence is between the ages of 20 and 40. The aim of this study was to assess the occupational impact of chronic urticaria and its treatment, by combining objective and patient-reported data. A monocentric observational study was performed using questionnaires over a 1-year period from 2021 to 2022 in chronic urticaria patients who were in a period of professional activity and agreed to participate. Of the 88 patients included, 55.7% assessed the occupational impact of their chronic urticaria as significant, and even more severe when chronic urticaria was poorly controlled. Some 86% of patients had symptoms at work, in a third of cases aggravated by work. However, occupational physical factors were not associated with an aggravation of inducible chronic urticaria. A total of 20% reported treatment-related adverse effects affecting their work. Despite low absenteeism, presenteeism and reduced productivity were important (> 20%). Six patients (6.8%) had difficulties keeping their work. For 72.7% of the patients, the occupational physician was not informed. The occupational impact of chronic urticaria should be discussed during consultations, particularly when it is insufficiently controlled. The occupational physician should be informed in order to support patients' professional project.
Congenital hyperinsulinism (CHI) is a clinically and genetically heterogeneous disorder that is the most common cause of permanent hypoglycemia in infants and children. More than 50% of the medically-unresponsive patients have focal disease. Which is characterized by a distinct region of Beta-cell hyperplasia in the pancreas, due to a somatic loss of a gene that regulates cell proliferation. Resection of the involved region cures most cases of focal HI. Therefore, preoperative identification and localization of focal HI lesions is useful for diagnostic confirmation and surgical guidance of patients with HI that fail pharmacological therapy and are being considered for surgery.

Insulinomas are benign insulin secreting neuroendocrine neoplasms located in the pancreas. They are the most common cause of endogenous hyperinsulinemic hypoglycemia in adults. Approximately 90% are solitary, benign and \< 2cm in diameter and therefore represent a challenge to localize. The small size of insulinomas makes detection by conventional imaging techniques such as contrast-enhanced CT (ceCT) and contrast-enhanced MRI challenging. As surgery appears to be the only available treatment option, it remains very critical to localize the tumor to facilitate pancreas preserving surgery. Endoscopic ultrasound is well established in the detection of insulinomas. However, this technique is operator dependent, invasive, and the visualization of the pancreas tail is not always possible. Therefore better imaging techniques to detect these lesions are needed for surgical planning.

Though not FDA approved, noninvasive imaging with 18F-fluoro-L-DOPA (FDOPA) is considered an integral part of standards of care management to identify focal lesions in CHI and potentially insulinomas. This is based on the fact that 18F-DOPA is selectively taken up by neuroendocrine cells, and thus, in focal HI, dense collections of endocrine cells can be visualized by an experienced radiologist. This study aims to determine if using combined positron emission tomography and magnetic resonance imaging will better localize the lesions and help the investigators determine which areas of the pancreas are affected, and assist with the surgical plan.
High (free) sugar intakes can increase self-reported energy intake and are associated with unfavourable cardiometabolic health. However, sugar source may modulate the effects of sugars due to several mechanisms including the food matrix. The aim of this review was to assess the current state of evidence in relation to food source effects on the physiological responses to dietary sugars in humans relevant to cardiometabolic health. An additional aim was to review potential mechanisms by which food sources may influence such responses. Evidence from meta-analyses of controlled intervention trials was used to establish the balance of evidence relating to the addition of sugars to the diet from sugar-sweetened beverages, fruit juice, honey and whole fruit on cardiometabolic outcomes. Subsequently, studies which have directly compared whole fruit with fruit juices, or variants of fruit juices, were discussed. In summary, the sources of sugars can impact physiological responses, with differences in glycaemic control, blood pressure, inflammation, and acute appetite. Longer-term effects and mechanisms require further work, but initial evidence implicates physical structure, energy density, fibre, potassium and polyphenol content, as explanations for some of the observed responses.
Newborn bathing will be done by the same nurse for each newborn in the study group. Since the evening hours are thought to be calmer for the baby bath, the hours between 22:00-24:00 will be chosen. Each newborn will be disinfected with only water beforehand and showered in the sinks used to wash the baby in the clinic. Bath time will be limited to two minutes. Newborns will be dried and dressed immediately after bathing. Monitor probes for monitor follow-ups and blood pressure cuffs will be connected to prevent extra touching during measurements.
FIELD: medicine. SUBSTANCE: method involves mixing solution fibrinogen precipitate/Factor XIII with thrombin under conditions providing inhibition of thrombin capability to form occlusions. This mixture is applied on body site under conditions influencing thrombin and converting fibrinogen to fibrin thickening agent. Syringe or one-single package can be used for administration of fibrin thickening agent. Invention can be used at different surgery operations in human and animals. EFFECT: improved method of administration. 14 cl
The invention relates to an application of beta hydroxyisovaleryl shikonin in preparing a medicament for treating prostatic cancer. The prostatic cancer is hormonal independent prostatic cancer. When 5*105 prostatic cancer cells exist per milliliter, the usage amount of the beta hydroxyisovaleryl shikonin is 0.5-10 microns. The invention explores a new medical purpose of the beta hydroxyisovaleryl shikonin and exploits a new application field. The beta hydroxyisovaleryl shikonin selectively inhabits the activity of tumor cells and has small toxicity for normal cells, i.e. the inventor invents an effective dose performing a difference action on the normal cells and the tumor cells, indicating that the beta hydroxyisovaleryl shikonin can be used as an anticancer medicament.
The dosage of sodium ferric gluconate complex in sucrose injection is expressed in terms of mg of elemental iron. Each 5 mL sterile, single dose vial contains 62.5 mg of elemental iron (12.5 mg/mL).

Do not mix sodium ferric gluconate complex in sucrose injection with other medications or add to parenteral nutrition solutions for intravenous infusion. The compatibility of sodium ferric gluconate complex in sucrose injection with intravenous infusion vehicles other than 0.9% sodium chloride has not been evaluated. Parenteral drug products should be inspected visually for particulate matter and discoloration before administration, whenever the solution and container permit. If diluted, use immediately.

Sodium ferric gluconate complex in sucrose injection treatment may be repeated if iron deficiency reoccurs.
One placebo tablet orally with food twice daily (b.i.d.) for 4 weeks followed by placebo b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
Intermittent erlotinib administration (21-day cycle). Erlotinib dose given at 150mg.
Throughout the experiment, the participants remained seated in a sitting position. The trial began with the chamber's temperature at 22-24 °C and 40-50% relative humidity for 20 minutes. After this period, the temperature within the chamber dropped by 4 degrees every 20 minutes. After 80 minutes (the chamber's temperature was 10°C and 40-50%), a radiator heater was placed in front of the participants to increase the temperature of their extremities. Simultaneously, the investigators increased the temperature of the chamber to 22-24 °C and 40-55% relative humidity, and the participants remained in the same sitting position for 20 minutes. Following this period, an occlusion foot test was performed to observe any hemodynamic changes in the foot. The test consisted of a 5-minute ''baseline'' phase, a 5-minute ''occlusion'' phase, and a 5-minute ''release'' phase. Before and after the trial, participants provided blood and urine samples.
The invention discloses a traditional Chinese medicine composition for treating infantile diarrhea. Orally taken medicine in the composition is prepared from the root of Chinese pulsatilla, Chinese yams, fried gorgon fruits, pomegranate bark, radix saussureae lappae, myristica fragrans, rhizoma atractylodis macrocephalae, poria cocos, the root of kudzu vine, allium macrostemon, the shell of areca nuts, coptis chinensis and dried tangerine or orange peel. If heat diarrhea appears in the symptom, talc, rhizoma atractylodis, mangnolia officinalis and coix seeds are added. If cold diarrhea appears in the symptom, agastache rugosus, purslane herb, fructus forsythia and saposhnicovia divaricata are added. If poor appetite, inability to eat and spleen-kidney yang deficiency diarrhea appear in the symptom, charred triplet, endothelium corneum gigeriae galli, the fruit of Chinese magnoliavine and syzygium aromaticum are added. External medicine is prepared from fennel, cassia bark, fistular onion stalk, raw wheat germ, folium isatidis, herba asari cum radice, amur cork-tree and dandelion. The traditional Chinese medicine composition has the effects of stopping pain, regulating qi-flowing for strengthening the spleen, tonifying the spleen, lung and kidney, tonifying middle-Jiao and qi and invigorating splenic yang for checking diarrhea, and mainly treats diarrhea caused by the irregular spleen and stomach and weakness of the spleen and stomach. The preparation process is simple and convenient, the toxic and side effects are small, medicine applying is convenient, and the medicine can be easily prepared into new medicine with low cost. The medicine can directly reach the focus and is shot in healing time, and relapse is avoided after healing.
The trial will be conducted to evaluate the effectiveness of the model and to determine the impact of the Planned Behavior Theory based educational intervention on diabetes management and pregnancy outcomes.The research will be conducted in Women's Training and Research Hospitals in Istanbul. The sample group will be 70 subjects calculated by power analysis. Case and control groups will be determined by simple randomization. Sampling selection criteria; 24-28. they are pregnant women who are diagnosed with GDM between the weeks of gestation, can communicate in Turkish, are literate, have no GDM in their previous pregnancies, have a personal contact number and e-mail address, and plan to give birth at the hospital where the study will be conducted. Research data will be collected by the researcher between the 28th week of gestation and the 12th week of postpartum through the Diabetes Intention, Attitude and Behavior Questionnaire, Personal Data Collection Form, Metabolic Control Variables Form, Maternal and Infant Pregnancy Results Form. Case group; In addition to the training given in the hospital, the Training for Gestational Diabetes Based on Planned Behavior Theory will be given in three stages. Figures, percentage distributions, chi-square test, student t-test and analysis of variance will be used in the analysis of the data. As a result of the intervention made to the case group; It is expected to decrease complications due to diabetes in mothers, babies and newborns, to provide maternal metabolic control, to control the mother's weight and to shorten the duration of hospital stay.
The invention relates to perfumery and cosmetic industry, in particular, to a technology for producing cosmetic cream concentrates based on natural, biologically active components contained in sea buckthorn fruits, specifically, for producing emulsion creams of oil/water types. The objective of this invention is to create a method for producing cream concentrates from sea buckthorn fruit with a smaller number of technological steps and shorter time spent on their performance, using an economically beneficial raw materials. The method of producing cosmetic cream concentrate of sea buckthorn is as follows. At the first stage, the fruits of sea buckthorn are cleaned, washed to remove impurities and passed through a juicer to get juice. The obtained juice is filtered. To prepare emulsions from the juice, 400 ml of juice is placed into a beaker of 2 l by volume, 800 ml of refined olive oil is added and, while stirring continuously, the temperature of the mass is brought to 80C. After that, 130-133 g of emulsifier T-2 is added to the mass and stirred until the emulsifier is completely dissolved in the system (10-15 min). The mixing process is carried out until the mass reaches room temperature. Thereby, as a result of emulsification, an emulsion concentrate of the water/oil type is produced. The resulting emulsion has a yellowish-gray color and smells of sea buckthorn fruits.
FIELD: cosmetics. SUBSTANCE: invention relates to development of cosmetic agents used for problem skin care. Agent for problem skin care is made as gel and it comprises bladder wrack and green tea aqueous extracts, birch leaves, juniper, field horse-tail and Cayenne pepper aqueous-spirituous extracts and glycerol, carbopol, triethanolamine, leaf mustard, tangerine essential oil and water also. Agent improves microcirculation, softens and wets skin efficiently, shows heating effect. EFFECT: improved and valuable properties of agent. 3 cl, 2 tbl, 1 ex
BACKGROUND: Cervical cancer remains a significant public health concern in Europe. Effective introduction and scaling up of human papillomavirus (HPV) detection-based cervical cancer screening (CCS) requires a systematic assessment of health systems capacity. However, there is no validated capacity assessment methodology for CCS programmes, especially in European contexts. Addressing this gap, our study introduces an innovative and adaptable protocol for evaluating the capacity of CCS programmes across varying European health system settings.
METHODS: Our research team developed a three-step capacity assessment framework, incorporating a health policy review checklist, a facility visit survey, and key informants' interview guide followed by a strengths, weaknesses, opportunities and threats (SWOT) analysis. Piloting this comprehensive approach, we explored the CCS capacity in three countries: Estonia, Portugal and Romania. These countries were selected due to their contrasting healthcare structures and resources, providing a diverse overview of the European context.
RESULTS: Conducted over a period of 9 months, the capacity assessment covered multiple resources, 27 screening centres, 16 colposcopy and treatment centres and 15 key informant interviews. Our analysis highlighted both shared and country-specific challenges. A key common issue was ensuring high compliance to follow-up and management of screen-positive women. We identified considerable heterogeneity in resources and organization across the three countries, underscoring the need for tailored, rather than one-size-fits-all, solutions.
CONCLUSIONS: Our study's novelty lies in the successful development of this capacity assessment methodology implementable within a relatively short time frame, proving its feasibility for use in various contexts and countries. The resulting set of materials, adaptable to different cancer types, is a ready-to-use toolkit to improve cancer screening processes and outcomes. This research marks a significant stride towards comprehensive capacity assessment for CCS programmes in Europe. Future directions include deploying these tools in other countries and cancer types, thereby contributing to the global fight against cancer.
Elevation of calcium levels inside the oocyte is one of the most initial steps which takes place during normal fertilization (1). The interaction between the sperm and oocytes surface protein receptors may be the triggering event for oocyte activation during the process of fertilization (2). It is suggested that the process of intracellular Calcium elevation is triggered by binding of the sperm to the oocyte oolemma and hence the fertilization starts (3). Severe male factor couples might have compromised fertilization and pregnancy outcomes (4).

A prospective multicenter non-randomized study indicated that calcium ionophore could improve the fertilization as well as the clinical pregnancy rates in these patients (5). On the other hand, a randomized controlled trial did not find any significance for the use of calcium ionophore in the couples with poor ovarian reserve with regards the fertilization and clinical pregnancy rates (6). The purpose of this study is to determine the impact of the use of calcium ionophore on the ICSI outcomes in couples with severe male factor infertility. Investigators conduct a randomized controlled trial on the sibling oocyte to justify the use of calcium ionophore in these cases.
At the beginning and at the end of the 6-month study period, patients of the Control group will perform outpatient cardiological visits. During the 6-month at home, patients will be followed in the usual care model by GP.
Dual-antiplatelet therapy (DAPT) with aspirin and an inhibitor of the platelet P2Y12 receptor is necessary to prevent stent-related thrombotic complications after percutaneous coronary intervention (PCI). (1) Although continuation of DAPT confers substantial and durable benefits that extend beyond the local stented segment, bleeding risk also increases with continued exposure to antiplatelet therapy. (2) Current guidelines give fixed duration of DAPT after coronary intervention but many patients still having early stent thrombosis despite this fixed policy, while others, on the contrary, suffer minor and major bleeding events. These clinical situations should raise the possibility of individualizing therapy. (5) The rationale of this study is to find a new method to tailor the optimal duration of DAPT for each patient by balancing long-term risks for both coronary thrombosis and major bleeding (MB).

The HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol concomitantly) score has long been used to predict bleeding events in patients on anticoagulation therapy. (3) Also, the CHA2DS2-VASc (congestive heart failure, hypertension, ≥75 years, diabetes, stroke/transient ischemic attack or thromboembolism, vascular disease, elderly, sex) score is a well-established system for prediction of thrombo-embolic events in patients with atrial fibrillation. (4) The aim of the present study is to evaluate the predictive ability of these 2 scoring tools when applied to patients undergoing PCI.